Overview
The Laboratory for Antiviral Research (LAR) at the University at Buffalo School of Pharmacy and
Pharmaceutical Sciences is conducting a multisite clinical research program to establish a Drug
Interactions and TDM Registry. The goal is to accumulate plasma HIV-1 protease inhibitor concentration
data along with adherence information and concurrent medications. This extensive population data will
allow us to determine the impact of complex drug interactions on protease inhibitor plasma concentrations
during chronic HIV pharmacotherapy. This registry is available to health care providers treating HIV patients.
PIs and NNRTIs
Presently the TDM registry is focused on measuring the following protease inhibitors in human plasma for the following:
| Protease Inhibitors: |
NNRTIs: |
| Amprenavir
|
Efavirenz
|
| Indinavir
|
| Ritonavir
|
| Lopinavir
|
| Nelfinavir + M8 metabolite
|
| Saquinavir |
| Atazanavir
|
Tipranavir  HPLC method for Tipranavir
|
NNRTIs and NRTIs
In the future, the TDM Registry may measure the following drug concentrations:
| NNRTIs: |
NRTIs: |
| Delavirdine
|
Abacavir
|
| Nevirapine
|
Lamivudine
|
The data generated from this service is
to be used solely for research purposes. All health care providers MUST be aware that our program is investigational in nature and�it is �of unproven clinical
benefit to patients. The Laboratory for Antiviral Research assumes no liability
for the interpretation, clinical use, or patient safety that may result from the
use of information provided by the registry. All investigators are required to
obtain informed consent from all patients prior to collecting blood samples for
TDM.
|
